Other

Finance Lease Liability Undiscounted Excess Amount

West Pharmaceutical Services Finance Lease Liability Undiscounted Excess Amount decreased by 20.0% to $400.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from $200.00K to $400.00K. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryLeverage
SignalLower is better
VolatilityModerate
First reportedQ1 2026
Last reportedQ1 2026

How to read this metric

Higher values indicate a larger interest component within the lease structure, impacting future earnings.

Detailed definition

This represents the interest component of finance lease liabilities, calculated as the difference between the total undi...

Peer comparison

Standard disclosure for finance leases; comparable across firms with significant capital lease portfolios.

Metric ID: other_finance_lease_liability_undiscounted_excess_amount

Historical Data

6 periods
 Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$300.00K$300.00K$200.00K$500.00K$500.00K$400.00K
QoQ Change—+0.0%-33.3%+150.0%+0.0%-20.0%
YoY Change———+66.7%+66.7%+100.0%
Range$200.00K – $500.00K
CAGR+25.9%
Avg YoY Growth+77.8%
Median YoY Growth+66.7%

Frequently Asked Questions

What is West Pharmaceutical Services's finance lease liability undiscounted excess amount?
West Pharmaceutical Services (WST) reported finance lease liability undiscounted excess amount of $400.00K in Q1 2026.
How has West Pharmaceutical Services's finance lease liability undiscounted excess amount changed year-over-year?
West Pharmaceutical Services's finance lease liability undiscounted excess amount increased by 100.0% year-over-year, from $200.00K to $400.00K.
What does finance lease liability undiscounted excess amount mean?
The interest portion of finance lease obligations that bridges the gap between undiscounted payments and the balance sheet liability.